Overview

* Aclaris Q2 revenue beats analyst expectations despite yr/yr decline, per LSEG data

* Net income for Q2 beats analyst estimates despite reporting a net loss, per LSEG data

* Co expects cash runway to fund operations into the second half of 2028

Outlook

* Company expects cash runway to fund operations into H2 2028

* Aclaris exploring non-dilutive opportunities to extend cash runway

* Company anticipates Phase 2 bosakitug results in H2 2026

* Aclaris expects Phase 1a ATI-052 results by early 2026

Result Drivers

* PHASE 2A TRIAL - Positive results from ATI-2138 trial confirm tolerability and show strong efficacy signal, validating ITK as therapeutic target

* REPORTED LOSS - Net loss was $15.4 million for the second quarter of 2025 compared to $11.0 million for the second quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.78 $1.37

Revenue mln mln (7

Analysts

)

Q2 Net Beat -$15.43 -$16.40

Income mln mln (7

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Aclaris Therapeutics Inc ( ACRS ) is $7.00, about 77.9% above its August 6 closing price of $1.55

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)